Galectin Therapeutics (NASDAQ:GALT) had its target price increased by analysts at Roth Capital from $3.00 to $8.00 in a report issued on Thursday, January 4th. The firm currently has a “buy” rating on the stock. Roth Capital’s price objective points to a potential upside of 61.62% from the company’s current price.

A number of other research analysts have also weighed in on the company. ValuEngine lowered Galectin Therapeutics from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. Zacks Investment Research lowered Galectin Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 8th. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective (up from $6.00) on shares of Galectin Therapeutics in a report on Thursday, December 7th. Finally, Seaport Global Securities reissued a “buy” rating and issued a $5.00 price objective on shares of Galectin Therapeutics in a report on Friday, October 6th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company’s stock. Galectin Therapeutics has a consensus rating of “Hold” and a consensus target price of $5.55.

Galectin Therapeutics (NASDAQ GALT) traded down $0.23 during trading on Thursday, reaching $4.95. The company’s stock had a trading volume of 140,784 shares, compared to its average volume of 1,091,822. Galectin Therapeutics has a 52 week low of $0.97 and a 52 week high of $6.74. The stock has a market capitalization of $192.45, a PE ratio of -9.42 and a beta of 2.54.

Galectin Therapeutics (NASDAQ:GALT) last announced its quarterly earnings data on Tuesday, November 7th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.02. equities analysts expect that Galectin Therapeutics will post -0.52 EPS for the current fiscal year.

In related news, major shareholder Fund L.P. 10X sold 244,444 shares of the firm’s stock in a transaction dated Friday, January 26th. The stock was sold at an average price of $5.43, for a total transaction of $1,327,330.92. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director James C. Czirr sold 205,144 shares of the firm’s stock in a transaction that occurred on Thursday, January 25th. The shares were sold at an average price of $5.45, for a total value of $1,118,034.80. The disclosure for this sale can be found here. 38.80% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently modified their holdings of the business. Northern Trust Corp grew its holdings in Galectin Therapeutics by 4.4% in the second quarter. Northern Trust Corp now owns 75,097 shares of the company’s stock valued at $185,000 after purchasing an additional 3,176 shares during the period. Virtu KCG Holdings LLC grew its holdings in Galectin Therapeutics by 24.4% in the second quarter. Virtu KCG Holdings LLC now owns 107,203 shares of the company’s stock valued at $264,000 after purchasing an additional 21,008 shares during the period. Advisor Group Inc. grew its holdings in Galectin Therapeutics by 10.4% in the second quarter. Advisor Group Inc. now owns 484,000 shares of the company’s stock valued at $1,191,000 after purchasing an additional 45,700 shares during the period. Finally, Vanguard Group Inc. grew its holdings in Galectin Therapeutics by 18.2% in the second quarter. Vanguard Group Inc. now owns 871,510 shares of the company’s stock valued at $2,144,000 after purchasing an additional 134,165 shares during the period. 10.70% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This article was reported by Marea Informative and is the sole property of of Marea Informative. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://www.mareainformativa.com/2018/01/30/galectin-therapeutics-galt-price-target-raised-to-8-00-updated-updated-updated.html.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.

Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.